Efficacy of low-dose imatinib in chronic-phase chronic myelogenous leukemia patients

S. Kobayashi · F. Kimura · A. Kobayashi · K. Sato · K. Motoyoshi

Published online: 4 October 2008
© Springer-Verlag 2008

Erratum to: Ann Hematol
DOI 10.1007/s00277-008-0589-2

The presentation of Table 1 was incorrect. The correct version is given below.

Table 1 Baseline characteristics of patients

Characteristic	Patients (n=34)	300 mg/day (n=17)	≥400 mg/day (n=17)
Age at the time of imatinib initiation, years			
Median	55	56	55
Range	31–77	34–77	31–67
Male, number (%)	26 (76.5)	11 (64.7)	15 (88.2)
Sokal score, number (%)			
Low	10 (29.4)	4 (23.5)	6 (35.3)
Intermediate	11 (32.4)	5 (29.4)	6 (35.3)
High	13 (38.2)	8 (47.1)	5 (29.4)
Time from diagnosis to imatinib initiation, months			
Median	1	2	1
Range	0–81	0–81	0–56
Treatment history, number (%)			
Total	8 (23.5)	5 (14.7)	3 (8.8)
Hydroxyurea	3 (8.8)	2 (5.9)	1 (2.9)
Hydroxyurea and Interferon- α	5 (14.7)	3 (8.8)	2 (5.9)

Funding and conflicts of interest No relevant conflicts of interest to declare.

Data from this study have not been previously published.

The online version of the original article can be found at <http://dx.doi.org/10.1007/s00277-008-0589-2>.

S. Kobayashi · F. Kimura · A. Kobayashi · K. Sato · K. Motoyoshi
Division of Hematology, Department of Internal Medicine,
National Defense Medical College,
3-2 Namiki,
Tokorozawa, Saitama 359-8513, Japan

K. Motoyoshi (✉)
Department of Internal Medicine,
National Defense Medical College,
3-2 Namiki,
Tokorozawa, Saitama 359-8513, Japan
e-mail: motoyosi@ndmc.ac.jp